Sigma’s growth plan
May 8, 2014
AT its annual general meeting,
Sigma Pharmaceuticals Limited ceo
Mark Hooper told shareholders he
believed the company was now in a
position to grow.
Sigma posted a full year profit of
$53.5m after tax (breaking news 27
Mar) and Hooper said cash from
its Clayton property was being
reinvested into Sigma’s acquisition
of CHS (PD 27 Mar), described as
an “exciting growth opportunity”
that the company expected would
contribute about $3.5m to EBITDA
in its first full year under Sigma’s
ownership.
The company intended to invest
in driving operational efficiencies
in the Brisbane and Sydney
distribution centres and had
accordingly earmarked up to $15m
to be spent in 2014, with “similar
levels of investment likely to be
required” over the next three years,
Hooper said.
“A site has been identified for
Brisbane, with the business case
being further developed.
“The Sydney investment is in early
planning stages.”
To read more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 14
